JPMorgan lowered the firm’s price target on Ardent Health (ARDT) to $15 from $18 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $23 from $24 at Leerink
- Ardent Health price target lowered to $20 from $24 at KeyBanc
- Sell Rating for Ardent Health Partners Due to Anticipated State Directed Payment Cuts and Profitability Challenges
- Ardent Health Reports Strong Q2 2025 Results
- Ardent Health reports Q2 EPS 52c, consensus 32c